The ANXA1 Knockout HAP1 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HAP1 cell line, designed to disrupt the ANXA1 gene and create a loss-of-function model. This mixed clonal population retains the genetic background of the host while introducing heterogeneous disruptions at the target locus, enabling robust assessment of ANXA1-dependent phenotypes without the selection of a single clone. Such polyclonal knockout populations mitigate clonal variability and are well-suited for pooled functional assays and drug screening applications where consistent gene disruption is essential.
HAP1 is a near-haploid human cell line originating from the KBM-7 chronic myeloid leukemia (CML) blast crisis patient isolate. Its haploid karyotype, with the exception of a disomic chromosome 8, simplifies genetic manipulation and facilitates the generation of clean knockout models, making HAP1 a preferred platform for haploid genetic screens. The cell line retains key signaling pathways relevant to hematopoietic malignancies, including those regulated by receptor tyrosine kinases, NF-??B, and ERK cascades. This background is particularly informative for studying genes involved in proliferation, apoptosis, and inflammation within a leukemic context.
ANXA1 (annexin A1) functions as a glucocorticoid-induced anti-inflammatory protein that suppresses cytosolic phospholipase A2 (cPLA2/PLA2G4A) activity, thereby limiting arachidonic acid release and downstream eicosanoid biosynthesis. In addition, ANXA1 binds to the formyl peptide receptor 2 (FPR2/ALX) to transduce extracellular signals that modulate key intracellular pathways. Upstream regulators of ANXA1 expression include glucocorticoids (acting through the glucocorticoid receptor, GR), TNF-??, IL-6, EGF, and TGF-??. Once expressed or secreted, ANXA1 modulates signaling through interaction partners such as S100A11, BAD, and EGFR, and regulates the activities of ERK1/2, NF-??B, and caspases. Thus, ANXA1 sits at a nexus connecting inflammatory cytokine signaling, growth factor receptors, and apoptotic machinery.
In the HAP1 leukemic context, loss of ANXA1 is expected to perturb the balance between proliferation and apoptosis, and to alter the cellular response to inflammatory stimuli and glucocorticoids. The near-haploid genome of HAP1 cells ensures that single-copy gene disruption translates more directly into functional outcomes, providing a clear readout in genetic perturbation experiments. Researchers can employ this model to dissect ANXA1??s role in BCR-ABL1-independent survival mechanisms characteristic of CML blast crisis, to evaluate its impact on NF-??B-mediated transcriptional programs, and to investigate its interactions with receptor tyrosine kinases such as EGFR that are often dysregulated in cancer.
This polyclonal knockout population supports a broad range of experimental applications, including real-time PCR and immunoblotting to confirm gene disruption and pathway activation, NF-??B reporter assays to assess inflammatory signaling, and flow cytometry to quantify apoptosis and cell cycle changes. Migration and invasion assays can be employed to study ANXA1??s influence on cancer cell motility, while co-immunoprecipitation and phospho-ERK analysis enable characterization of protein-protein interactions and ERK signaling dynamics. Given ANXA1??s involvement in glucocorticoid sensitivity, this model is also valuable for validating drug targets in inflammatory diseases and oncology. For further details or to discuss assay customization, please contact the Ascent Research support team.
